Autoimmune myasthenia gravis
- 1 March 2009
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 9 (3) , 351-358
Abstract
Myasthenia gravis (MG) is an autoimmune neuromuscular transmission disorder where well-defined autoantibodies against muscle and muscle cell membrane molecules are directly pathogenetic. All MG patients should be defined for subtype, as such a subclassification has treatment consequences. Ocular MG, early-onset MG, late-onset MG, MG with thymoma, MG with anti-muscle-specific tyrosine kinase antibodies and MG with no defined antibodies constitute the six MG categories. The MG diagnostic process includes neurophysiology, neuroimmunology, neuropharmacology and imaging. In addition to symptomatic therapy with acetylcholine esterase inhibitors, most patients need thymectomy and/or immunosuppressive drugs. Today's treatment is not immunospecific and far from antigen-specific, even if the pathogenesis is known in detail. Strategies for acetylcholine receptor tolerance induction, manipulating acetylcholine receptor antigen presentation or suppressing acetylcholine receptor-specific B-cells or plasma cells work in experimental MG, but have not yet been attempted properly for the human disease, or they do not work. Apart from the 10-15% of patients with paraneoplastic MG, the cause of the disease is not known. Until curative or antigen-specific therapy become available, the well-established treatment gives good-to-excellent results in most patients, with acceptable quality of life and no increased mortality. Acute and intensive care treatment during MG exacerbation is a cornerstone in the treatment.Keywords
This publication has 39 references indexed in Scilit:
- Rebooting the Immune System with High‐Dose Cyclophosphamide for Treatment of Refractory Myasthenia GravisAnnals of the New York Academy of Sciences, 2008
- Strategies for Treating AutoimmunityAnnals of the New York Academy of Sciences, 2008
- Myasthenia Gravis and the Tops and Bottoms of AChRsAnnals of the New York Academy of Sciences, 2008
- Treatment and Clinical Research in Myasthenia GravisAnnals of the New York Academy of Sciences, 2008
- Antigen‐specific Apheresis of Pathogenic Autoantibodies from Myasthenia Gravis SeraAnnals of the New York Academy of Sciences, 2008
- IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis†Brain, 2008
- Ocular myasthenia: diagnostic and treatment recommendations and the evidence baseCurrent Opinion in Neurology, 2008
- Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising careEuropean Journal of Neurology, 2007
- Artrogryposis multiplex congenita - a rare fetal condition caused by maternal myasthenia gravisActa Neurologica Scandinavica, 2006
- Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitorThe FASEB Journal, 2005